Molina Healthcare收入指引低于预期但上调全年EPS下限

Google raises annual spending estimates amid rapid AI infrastructure build-out
Investing.com -- Molina Healthcare stock is sliding 9.2% in pre-open trading after the managed care company reported second-quarter 2026 results after Wednesday’s close that beat earnings estimates but left investors rattled by a full-year revenue outlook that came in sharply below Wall Street’s expectations.
The company posted adjusted earnings per share of $1.51 for the quarter, topping the analyst consensus of approximately $1.39–$1.40, while revenue of roughly $10.87 billion landed essentially in line with forecasts — but the full-year 2026 revenue guidance held at approximately $42 billion, far below the analyst consensus of around $44.28 billion.
The earnings call, scheduled for the morning of July 23, added an additional layer of uncertainty heading into the pre-market session, with investors parsing CEO Joseph Zubretsky’s characterization of 2026 as the "trough year" for Medicaid pretax margins.
The company did raise its full-year adjusted EPS guidance to at least $5.25 from the prior floor of $5.00, but that upward revision was not enough to offset concern over the revenue gap, headwinds from Marketplace enrollment pressure, and startup costs tied to the Florida CMS Medicaid contract. Membership also continued to contract, with the company serving approximately 4.9 million members at quarter-end, down from 5.0 million in Q1.
The broader market offered no buffer, with the S&P 500 off 0.3%, the Dow Jones down 0.3%, and the Nasdaq lower by 0.4% in today’s session. Analyst sentiment heading into the print had been mixed — while several firms including TD Cowen and Truist lifted price targets meaningfully in mid-July, Barclays had already trimmed its target to $184 from $199 earlier in the month, signaling caution around the managed care outlook amid persistent medical cost pressures and Medicaid enrollment contraction.
Taken together, a beat on the bottom line proved insufficient to satisfy a market that had rallied the stock sharply in the weeks prior to earnings and was squarely focused on whether Molina could defend or improve its top-line trajectory. The combination of a revenue guidance miss, ongoing Medicaid cycle headwinds, and a muted macro backdrop converged to send shares to $201.27 in pre-market trading — near the lower end of the 52-week range relative to the recent recovery high.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.